Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase I Study of Inhaled Doxorubicin in Patients With Primary Lung Cancer or Cancer Metastatic to the Lung

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase I	Treatment	Completed	18 and over	NCI	MSKCC-99049 BMI-98-DOX-001, NCI-G00-1696, NCT00004930

Trial Description

Purpose:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Phase I trial to study the effectiveness of inhaled doxorubicin in treating patients who have primary lung cancer or lung metastases.

Eligibility:

• At least 18 years old
• At least 3 weeks since chemotherapy or radiation therapy
• No previous surgery to remove a lung
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will inhale doxorubicin every 3 weeks for up to three courses. Patients may receive additional treatment after a 3-month waiting period. Patients will be evaluated at 6 weeks.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Memorial Sloan-Kettering Cancer Center

Naiyer Rizvi, MD, Protocol chair		Ph: 212-639-3204; 800-525-2225

Registry Information
Official Title		Phase I and Clinical Pharmacologic Study of Inhaled Doxorubicin in Adults with Advanced Solid Tumors Affecting the Lungs
Trial Start Date		1999-07-27
Registered in ClinicalTrials.gov		NCT00004930
Date Submitted to PDQ		2000-01-13
Information Last Verified		2004-04-15
NCI Grant/Contract Number		P30-CA08748

Back to Top